Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Head & Neck 2Thoracic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Neoplasms 4Head and Neck Neoplasms 3Melanoma 2Lung Neoplasms 2Carcinoma, Squamous Cell 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Solid Tumor, Adult 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1Breast Neoplasms 1Brain Neoplasms 1Advanced Solid Malignancies 1

Interventions

Surveys and Questionnaires 114Exercise 103Blood Specimen Collection 99Radiotherapy 67Gemcitabine 64Bevacizumab 57Standard of Care 56Cisplatin 55Cyclophosphamide 51Capecitabine 50Carboplatin 49Docetaxel 47pembrolizumab 46Dexamethasone 46Paclitaxel 45Interviews as Topic 43Oxaliplatin 40Magnetic Resonance Spectroscopy 39Fluorouracil 37Methods 36Irinotecan 36Therapeutics 33Drug Therapy 33Radiosurgery 31Nivolumab 30Erlotinib Hydrochloride 27Educational Status 26Everolimus 24Leucovorin 23Control Groups 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Neoplasms × Tiragolumab × Clear all
NCT05394337 2026-05-05

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
10 enrolled
Tumor-Agnostic

Neoplasms

NCT06754501 2026-02-18

A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
4 enrolled
Tumor-Agnostic

Neoplasms

NCT03708224 2025-01-28

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

University of California, San Francisco

Phase 2 Recruiting
55 enrolled
Head & Neck

Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms

NCT05259319 2023-10-17

IMMUNOs-SBRT

Centre Georges Francois Leclerc

Phase 1 Unknown
92 enrolled
GenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡